Ieuan Jones
Overview
Explore the profile of Ieuan Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sangana R, Xu Y, Shah B, Tian X, Zack J, Shakeri-Nejad K, et al.
Clin Pharmacol Drug Dev
. 2024 Feb;
13(6):611-620.
PMID: 38389387
Omalizumab is an anti-IgE monoclonal antibody currently approved for the treatment of asthma, nasal polyps/chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. Omalizumab is available as an injection in...
2.
Iyer G, Darpo B, Xue H, Lecot J, Zack J, Bebrevska L, et al.
Clin Pharmacol Drug Dev
. 2024 Jan;
13(5):572-584.
PMID: 38284433
Icenticaftor (QBW251) is a potentiator of the cystic fibrosis transmembrane receptor. Based on its mechanism of action, icenticaftor is expected to provide benefits in patients with chronic obstructive pulmonary disease...
3.
Gauvreau G, Hohlfeld J, FitzGerald J, Boulet L, Cockcroft D, Davis B, et al.
Eur Respir J
. 2023 Feb;
61(3).
PMID: 36822634
Background: Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a potent inhaled neutralising antibody fragment against human...
4.
Singh D, Wild J, Saralaya D, Lawson R, Marshall H, Goldin J, et al.
Respir Res
. 2022 Feb;
23(1):26.
PMID: 35144620
Rationale: The long-acting β-agonist/long-acting muscarinic antagonist combination indacaterol/glycopyrronium (IND/GLY) elicits bronchodilation, improves symptoms, and reduces exacerbations in COPD. Magnetic resonance imaging (MRI) of the lung with hyperpolarized gas and gadolinium...
5.
Beier J, Watz H, Diamant Z, Hohlfeld J, Singh D, Pinot P, et al.
ERJ Open Res
. 2021 Apr;
7(2).
PMID: 33898609
Once-daily asthma treatment should prevent night-time deterioration, irrespective of the time of dosing. IND/GLY/MF, a fixed-dose combination of inhaled indacaterol acetate (IND, long-acting β-agonist (LABA)), glycopyrronium bromide (GLY, long-acting muscarinic...
6.
Chapman K, Watz H, Singh D, Hohlfeld J, Diamant Z, Jones I, et al.
Clin Drug Investig
. 2021 Apr;
41(5):489-492.
PMID: 33864631
No abstract available.
7.
Kazani S, Rowlands D, Bottoli I, Milojevic J, Alcantara J, Jones I, et al.
J Cyst Fibros
. 2020 Dec;
20(2):250-256.
PMID: 33293212
Background: This is the first-in-human study of icenticaftor, an oral potentiator of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) channel. Restoration of CFTR activity has shown significant clinical benefits,...
8.
Rowe S, Jones I, Dransfield M, Haque N, Gleason S, Hayes K, et al.
Int J Chron Obstruct Pulmon Dis
. 2020 Oct;
15:2399-2409.
PMID: 33116455
Rationale: Excess mucus plays a key role in COPD pathogenesis. Cigarette smoke-induced cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction may contribute to disease pathogenesis by depleting airway surface liquid and...
9.
Watz H, Hohlfeld J, Singh D, Beier J, Diamant Z, Liu J, et al.
Respir Res
. 2020 Apr;
21(1):87.
PMID: 32295593
Indacaterol (IND; 150 μg), glycopyrronium (GLY; 50 μg) and mometasone furoate (MF; 160 μg [high-dose ICS] and 80 μg [medium-dose ICS]) have been formulated as a once-daily (o.d.) fixed-dose combination...
10.
Fisch R, Jones I, Jones J, Kerman J, Rosenkranz G, Schmidli H
Ther Innov Regul Sci
. 2018 Sep;
49(1):155-162.
PMID: 30222466
The proof-of-concept (PoC) decision is a key milestone in the clinical development of an experimental treatment. A decision is taken on whether the experimental treatment is further developed (GO), whether...